We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...

We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.